Docoh
Loading...

39 results

Filter options loading...
Top filers
Top filing types
Recent filing years
DEF 14A
PCSA Processa Pharmaceuticals Inc
22 Apr 21
Definitive proxy
2:00pm
requirements summarized under “Stockholder Proposals” below. Leadership Structure and Risk Oversight Our Board of Directors is currently chaired by David … . Our Board of Directors performs this oversight role by using several different levels of review. In connection with its reviews of our operations
10-K/A
2020 FY
PCSA Processa Pharmaceuticals Inc
7 Apr 21
Annual report (amended)
4:23pm
of Directors and individual directors; and assisting our Board of Directors on corporate governance matters. Leadership Structure and Risk Oversight … business and the implementation of our business strategies. Our Board of Directors performs this oversight role by using several different levels
10-K
2020 FY
PCSA Processa Pharmaceuticals Inc
24 Mar 21
Annual report
8:00pm
of experienced employees and consultants to provide the necessary technical, quality and regulatory oversight of our CMOs. We anticipate … funded healthcare programs, such as Medicare and Medicaid, integrity oversight and reporting obligations, contractual damages, reputational harm
8-K
EX-1.1
PCSA Processa Pharmaceuticals Inc
6 Oct 20
Processa Pharmaceuticals Announces Pricing of $19.2 Million Public Offering and Uplisting to the Nasdaq Capital Market
4:05pm
is aware of any “significant deficiencies” or “material weaknesses” (each as defined by the Public Company Accounting Oversight Board) in its internal
424B4
PCSA Processa Pharmaceuticals Inc
5 Oct 20
Prospectus supplement with pricing info
4:16pm
and regulatory oversight of our CMOs. We anticipate that these CMOs will have the capacity to support both clinical supply and commercial-scale production … from participation in government funded healthcare programs, such as Medicare and Medicaid, integrity oversight and reporting obligations, contractual
S-1/A
olr5h cg6o90kgicwsx4
30 Sep 20
IPO registration (amended)
4:06pm
S-1/A
8z7rbftkfo2fmd2xx
16 Sep 20
IPO registration (amended)
8:00pm
S-1/A
EX-1.1
y6clswae8
16 Sep 20
IPO registration (amended)
8:00pm
S-1/A
by3a7divq5rrf9
17 Jul 20
IPO registration (amended)
5:25pm
10-K
k59yup7g4 ahqurwf
5 Mar 20
Annual report
7:00pm
S-1
nig07szpsh3cfp6oq8
13 Dec 19
IPO registration
5:32pm
DEF 14A
a9cgoolf 3yx4
26 Apr 19
Definitive proxy
5:02pm
10-K/A
cm8 2c051go
5 Apr 19
Annual report (amended)
9:40pm
10-K
qlc6lwr4f0o5aya
28 Mar 19
Annual report
5:25pm
424B3
qq2844t h4k
13 Nov 18
Prospectus supplement
9:39pm
10-Q
gucaonlj6nfbawx6ge
13 Nov 18
Quarterly report
9:37pm
424B3
w65gmy1h
9 Nov 18
Prospectus supplement
5:04pm
S-1/A
qol6j
30 Oct 18
IPO registration (amended)
4:19pm
S-1/A
rljbn42kv6168p8a
9 Oct 18
IPO registration (amended)
5:32pm
S-1/A
srpuaolgwt pedyt
13 Sep 18
IPO registration (amended)
8:00pm